MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2024 International Congress

    Clinical and Brain Morphological Characteristics of Early LRRK2-associated Parkinson Disease

    Q. Tao, S. Rahayel, C. Tremblay, A. Vo, A. Dagher (Montreal, Canada)

    Objective: To investigate the impact of LRRK2 mutation in Parkinson disease (PD) and to explore the preclinical markers of LRRK2 mutation carriers who will develop…
  • 2024 International Congress

    LRRK2 in Parkinson’s Disease: A per-domain rare-variant burden study

    S. Parlar, K. Senkevich, E. Yu, J. Ruskey, J. Ahmad, F. Asayesh, D. Spiegelman, C. Waters, O. Monchi, Y. Dauvilliers, N. Dupré, L. Greenbaum, S. Hassin-Baer, I. Miliukhina, A. Timofeeva, A. Emelyanov, S. Pchelina, R. Alcalay, E. Fon, Z. Gan-Or (Montreal, Canada)

    Objective: To study rare variant burden in different LRRK2 domains to investigate domain-based associations with Parkinson’s Disease (PD) and to identify functional variants in LRRK2.…
  • 2024 International Congress

    Slc2a13, a risk gene for Parkinson’s disease associated with Snca and Lrrk2

    JW. Li, GX. Zhang, T. Wang, ZC. Lin, N. Xiong (Wuhan, China)

    Objective: To exploit the potential function of the risk gene Slc2a13 in PD progression. Background: 越来越多的证据证实了总体遗传位点和候选基因对帕金森病的贡献,以及两个最确定的风险基因,即α-突触核蛋白(Snca)和富含亮氨酸的重复激酶2(Lrrk2)。Slc2a13 编码哺乳动物肌醇转运蛋白,被认为是一种群体依赖性风险基因。越来越多的证据支持这样一种观点,即 Slc2a13 活性的改变强调了 PD 的发展。剖析转运蛋白活性降低如何导致多巴胺能神经元变性和丧失,可能会进一步加深我们对功能的理解。 Method: A total of 338 cases…
  • 2024 International Congress

    MDSGene Update and Expansion: Clinical and Genetic Spectrum of LRRK2 Variants in Parkinson´s Disease

    C. Krüger, S-Y. Lim, A. Buhrmann, FL. Fahrig, C. Gabbert, N. Bahr, H. Madoev, C. Marras, C. Klein, K. Lohmann (Luebeck, Germany)

    Objective: To provide a comprehensive and systematic overview of published data on carriers of pathogenic variants in the LRRK2 gene, including demographic, clinical, and genetic…
  • 2024 International Congress

    Association of polygenic risk score of the LRRK2 gene for Parkinson’s disease with lysosomal hydrolase activities in the Russian Population based on genetic profile and established risk factors

    T. Usenko, K. Basharova, A. Bezrukova, K. Senkevich, I. Miliukhina, A. Timofeeva, E. Zakharova, S. Pchelina (Gatchina, Russian Federation)

    Objective: To studied a previously proposed polygenic risk scores (PRSs) for PD selected for the LRRK2 gene in a genetic data set of Russian population…
  • 2024 International Congress

    Characterisation and longitudinal significance of subjective cognitive decline in GBA and LRRK2 Parkinson’s disease

    L. Batzu, D. Urso, S. Rota, A. Podlewska, MA. Qamar, KR. Chaudhuri (London, United Kingdom)

    Objective: To investigate the clinical characteristics and predictive value associated with subjective cognitive decline (SCD) in people with Parkinson’s disease (PD) carrying pathogenic GBA or…
  • 2024 International Congress

    LRRK2 and GBA Founder Mutations and their Interactions in Parkinson’s Disease

    M. Kmiecik, G. Riboldi, R. Schneider, K. Stagaman, T. Filshtein Sonmez, A. Guan, M. Wetzel, P. Fontanillas, M. Holmes, S. Aslibekyan, L. Norcliffe-Kaufmann (Sunnyvale, USA)

    Objective: To evaluate the symptoms of Parkinson’s disease (PD) and time to diagnosis in single and dual carriers of LRRK2 G2019S and GBA N370S. Background:…
  • 2024 International Congress

    RBD Unmasked: LRRK2 and the Prodromal Path to Parkinson’s Disease

    M. Acharya, S. Datta, N. Ghosh, B. Chakraborty (Kharagpur, India)

    Objective: The primary objective is to analyze and compare the prevalence of RBD in LRRK2-positive individuals across different stages, including healthy controls (HC), prodromal Parkinson's…
  • 2024 International Congress

    Differences in Oculometric Measures between Patients with LRRK2-associated and Idiopathic Parkinson’s Disease

    R. Djaldetti, E. Raveh, J. Reiner, L. Franken, E. Harpaz, R. Kreitman, E. Ben-Ami (Petah Tikva, Israel)

    Objective: To examine the use of oculometric measures (OMs) as a tool to differentiate patients with Leucine-Rich Repeat Kinase (LRRK2) - associated (L2PD) and idiopathic…
  • 2024 International Congress

    Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

    Objective: Measure LRRK2 pathway activity in Parkinson’s Disease patients stratified using a genetic predictive classifier model. Background: Extensive research has shown that overactivation of the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 16
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley